Cell line · CVCL_1067
ACHN
Cancer cell line, Homo sapiens. Papillary renal cell carcinoma. 95 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. ACHN. Cell lines, record CVCL_1067. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1067
On this page
Cell line
As Cellosaurus gives it.
- Name
- ACHN
- Accession
- CVCL_1067
- RRID
- RRID:CVCL_1067
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 22Y
- Category
- Cancer cell line
- Diseases
- Papillary renal cell carcinoma (NCIt C6975); Papillary renal cell carcinoma (ORDO Orphanet_319298)
- Derived from
- Pleural effusion (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers95
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Inhibition of PLK1 helps to restrict c-Met-induced growth and therapeutic resistance of renal cancer cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironment. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RIOK2 Promotes Clear Cell Renal Cell Carcinoma Progression Through Cell Cycle Regulation. | Cancer Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Predicting Poor Efficacy of Cabozantinib in Advanced Renal Cell Carcinoma by Exploratory Metabolic Pathway Analysis and In Vitro Verification. | Cancer Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the ATX-LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
An Integrated Immunometabolic Signature Predicts Prognosis and Immunotherapy Response in ccRCC and Identifies UCN-Mediated Immune Evasion as a Therapeutic Vulnerability: Evidence from In Vitro and In Vivo Studies. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Global analysis of cancer cell responses to USP9X inhibition. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 95
See all 95 papersRelatives6
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | ACHN-IL2 | CVCL_W666 | Cell lines | |
| Derived from it | ACHN-luc2 | CVCL_5J27 | Cell lines | |
| Derived from it | ACSuR | CVCL_XI64 | Cell lines | |
| Derived from it | HyCyte ACHN KO-hTNFSF9 | CVCL_E1J4 | Cell lines | |
| Derived from it | HyCyte ACHN-Luc | CVCL_E3GP | Cell lines | |
| Derived from it | Ubigene ACHN IGF2BP3 KO | CVCL_D8DP | Cell lines |
Cell banks14
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-1611 | ATCC | |
| CCTCC | GDC0102 | Cellosaurus | |
| CLS | 300117 | CLS | |
| ECACC | 88100508 | ECACC | |
| IBRC | C10105 | Cellosaurus | |
| ICLC | HTL99007 | ICLC | |
| IZSLER | BS TCL 68 | Cellosaurus | |
| KCB | KCB 200611YJ | Cellosaurus | |
| KCLB | 21611 | KCLB | |
| NCBI_Iran | C206 | Cellosaurus |
1 to 10 of 14
See all 14 cell banksData dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1067
GET https://conductscience.org/api/cell-lines/v1/CVCL_1067/papers?page=2